晚期大肠癌化学治疗的新进展

近10年先后批准了6个新药用于治疗晚期大肠癌，包括伊立替康、卡培他滨、奥沙利铂、贝伐单抗、西妥昔单抗和帕妥尼单抗，新的治疗方案也不断涌现。与单用氟尿嘧啶一样，晚期大肠癌患者同样可从这3个细胞毒药物和3个靶向药物中获益。大量研究证实，随着这些新的药物和方案的应用，晚期大肠癌的中位生存期可以从最好支持治疗的6～8个月延长到联合化疗加靶向药物的30个月以上。本文试对晚期大肠癌化学治疗的新进展进行一个综述性评价。

Advances in the chemotherapy of advanced colorectal cancer

In the treatment of advanced colorectal cancer, six new agents including irinoteean,capecitabine, oxaliplatin, bevacizumab, cetuximab, and panitumumab have been licensed in the past decade, and new regimens has increased substantially. In addition to the single agent fluorouracil, patients can also benefit from the three cytotoxic drugs and three molecularly targeted agents. Many clinical trials investigating the use of these agents have demonstrated a significant increase in median survival in patients with advanced colorectal cancer-from 6 to 8 months to more than 30 months with the use of combination chemotherapy and targeted agents.